Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05625412 | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | PHASE1 | COMPLETED | 70 | — | — | Dec 9, 2022 | May 12, 2025 | Jun 13, 2025 | 35 | United States, Argentina +7 |
| Arm | Type | Description |
|---|---|---|
| BMS-986360 | EXPERIMENTAL | - |
| BMS-986360 + Docetaxel | EXPERIMENTAL | - |
| BMS-986360 + Nivolumab | EXPERIMENTAL | - |
| BMS-986360 + Capecitabine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986360 | DRUG | Specified dose on specified days |
| Docetaxel | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
| Capecitabine | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants in Part 1 must have histologic or cytologic confirmation of non-small cell lung cancer (NSCLC), metastatic triple negative breast cancer (mTNBC), squamous cell carcinoma of head and neck (SCCHN), pancreatic adenocarcinoma (PAAD), renal cell carcinoma (RCC), micros...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |